Ignite Creation Date:
2024-05-05 @ 4:58 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00358449
Status:
COMPLETED
Last Update Posted:
2018-07-24
First Post:
2006-07-27
Brief Title:
Intravenous Mepolizumab In Children With Eosinophilic Esophagitis
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Randomized Double-blind Parallel Group Clinical Trial to Assess Safety Tolerability Pharmacokinetics and Pharmacodynamics of Intravenous Mepolizumab SB240563055mgkg 25mgkg or 10mgkg in Pediatric Subjects With Eosinophilic Esophagitis Aged 2 to 17 Years Study MEE103219
Status:
COMPLETED
Status Verified Date:
2018-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the safety tolerability pharmacokinetics and pharmacodynamics of intravenous mepolizumab in pediatric subjects with eosinophilic esophagitis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None